Citations

Clear

2117 citation(s) found for "Mayo, Steven".

Abstract 3135: Comparative analysis of phenotypic markers of DPD activity as biomarkers of 5-FU toxicity
Bembenek, Brianna M. , Offer, Steven M. , Offer, Steven M , Bouchonville, Kelly J. , Largiadèr, Carlo R.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 3135-3135

10.1158/1538-7445.am2026-3135 Get It

Abstract Nearly 300,000 cancer patients are treated with fluoropyrimidine chemotherapy in the U.S. annually. Approximately one-third of patients experience severe and life-threatening toxicities, which can result in death. Deleterious genetic variants in DPYD, which encodes the rate-limiting enzyme of fluoropyrimidine catabolism (dihydropyrimidine dehydrogenase, DPD), have been correlated with severe toxicity in clinical studies. However, these variants explain only 10-30% of toxicity cases. Phenotypic measures of DPD function are attractive biomarkers of fluoropyrimidine toxicity risk with the potential to identify unknown causes of DPD deficiency. In this study, we compared two measures of DPD enzyme activity, blood plasma dihydrouracil to uracil ratio (UH2:U) and direct measurement of DPD activity in peripheral blood mononuclear cells (PBMCs) using 204 subjects with comprehensive DPYD genotype data. DPD PBMC measurements showed higher overall inter-individual variation compared to UH2:U ratios. Low correlation between UH2:U and PBMC measurements were noted for matched samples taken from the same subject. As expected, DPD metabolites (U and UH2) correlated with UH2:U ratio; however, no correlation was noted between U or UH2 levels and the PBMC DPD activity. Furthermore, when data were analyzed by genotype, no correlations were noted between UH2:U and PBMC DPD activity. We observed the expected decrease in UH2:U ratio for carriers of the four clinically tested DPYD variants and identified two novel variants associated with a significantly decreased UH2:U ratio. To further investigate the impact of rare genotypes and previously identified DPYD haplotypes on the UH2:U ratio, additional cohorts of 1994 and 500 subjects, enriched for specific genotypes, were utilized. Our results suggest that phenotyping may have limited validity as a single test when predicting DPD deficiency at an individual level and call into question the often-reported belief that PBMC DPD activity represents the "gold standard" for identifying DPD deficiency. Additional studies are needed to investigate correlations between phenotypic measures and 5-FU toxicity in patients, potentially as secondary biomarkers in conjunction with genetic tests. Citation Format: Brianna Bembenek, Kelly Bouchonville, Carlo Largiadèr, Steven M. Offer. Comparative analysis of phenotypic markers of DPD activity as biomarkers of 5-FU toxicity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 3135.
Abstract 3137: Partial alternative splicing in carriers of DPYD rs75017182 explains modest association with severe 5-FU toxicity to 5-FU
Hahn, Lauryn Allyn, Schwartz, Ryan, Krause, Hannah Marie, Jiang, Lulu, Bembenek, Brianna M. , Offer, Steven M. , Offer, Steven M , Swartz, Ryan Jonathan, Bouchonville, Kelly J.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 3137-3137

10.1158/1538-7445.am2026-3137 Get It

Abstract Dihydropyrimidine dehydrogenase (DPD, encoded by the DPYD gene) is the rate-limiting enzyme in the catabolism of the widely used chemotherapeutic drug 5-fluorouracil (5-FU). Genetic variations in DPYD are predictive biomarkers of 5-FU toxicity. One such biomarker, rs75017182 (the causal allele linked to the “HapB3” haplotype), has been suggested to promote alternative splicing of DPYD, leading to expression of an inactive proteoform. However, carriers of rs75017182 exhibit only moderately increased risk of 5-FU toxicity and modestly decreased ex vivo DPD activity compared to carriers of another well-studied splice variant, rs3918290 (*2A). We hypothesized that, unlike *2A, the rs75017182 variant does not cause obligate alternative splicing but instead promotes partial alternative splicing. To test this, we generated dual-fluorescent minigene reporter constructs containing either the G (wildtype) or C (variant) allele. In our minigene system, alternative splicing was elevated in cells transfected with C-containing vectors via flow cytometry, though levels were lower than those observed in a parallel *2A model. To investigate contributions of other variants in LD with rs75017182, we expanded the reporter to include additional relevant genomic regions. The analyses were complemented by the study of in vivo splicing in cells engineered to harbor various combinations of variants and in lymphoblastoid lines carrying specific genotype combinations. Overall, our findings demonstrate that rs75017182-C promotes only partial alternative splicing, eliciting a modest decrease in DPD activity and explaining its comparatively weak association with severe 5-FU toxicity. Additional variants in LD have a minimal impact on splicing and 5-FU sensitivity. Citation Format: Lauryn Allyn Hahn, Ryan Schwartz, Hannah Marie Krause, Lulu Jiang, Brianna Bembenek, Kelly Bouchonville, Steven M. Offer. Partial alternative splicing in carriers of DPYD rs75017182 explains modest association with severe 5-FU toxicity to 5-FU [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 3137.
Abstract 2712: MPACT-DPD: An interpretable machine learning classifier for predicting the functional impact of DPYD missense variants.
Jiang, Lulu , Swartz, Ryan Jonathan, Hahn, Lauryn Allyn, Bembenek, Brianna M. , Krause, Hannah Marie, Offer, Steven M. , Offer, Steven M , Bouchonville, Kelly J.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 2712-2712

10.1158/1538-7445.am2026-2712 Get It

Abstract 5-Fluorouracil (5-FU) is a widely prescribed chemotherapy for colorectal, breast, gastric, and head and neck cancers. The drug inhibits thymidylate synthase, blocking DNA synthesis and causing cytotoxic stress that halts tumor growth. However, patients carrying deleterious variants in DPYD, the gene encoding the rate-limiting enzyme in 5-FU metabolism (dihydropyrimidine dehydrogenase, DPD), can experience fatal toxicity due to impaired drug clearance and accumulation of 5-FU metabolites. Current pharmacogenetic screening guidelines in the U.S. recommend testing for few of the >2,000 nonsynonymous variants that have been reported for DPYD, leaving patients with rare, uncharacterized mutations at risk. To interpret expanded testing, however, a means to classify DPYD variants of unknown significance is needed. To address this, we developed MPACT-DPD, a random-forest-based classifier that accurately predicts the functional impact of DPYD missense variants. Our model was trained on in-vitro activity of 156 variants and leveraged a feature set of biochemical, evolutionary, and AlphaFold3-derived structural features. We optimized hyperparameters using ten-fold stratified cross-validation and evaluated model performance with Matthews correlation coefficient (MCC) to account for moderate class imbalance (7:3 neutral to deleterious). It achieved exceptional performance, with a Matthews correlation coeffient (MCC) of 0.906 and an accuracy of 95.1% on an independent validation set (n=43). Furthermore, a SHAP (SHapley Additive exPlanations)-based interpretability analysis revealed cofactor proximity and residue conservation as the key drivers of predictions. MPACT-DPD showed superior performance at variant classification against other tools, including a DPYD gene-specific variant classifier, and has the potential to expand pre-treatment genetic screening to improve the safety of personalized 5-FU-based chemotherapy. Citation Format: Lulu Jiang, Ryan Jonathan Swartz, Lauryn Allyn Hahn, Brianna Bembenek, Hannah Marie Krause, Kelly Bouchonville, Steven M. Offer. MPACT-DPD: An interpretable machine learning classifier for predicting the functional impact of DPYD missense variants [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 2712.
Outcomes of soft-tissue reconstruction for isolated type III internal hemipelvectomy
Willborg, Brooke E. , Salinas, Cristina A., Rode, Matthew M. , Mullen, Barbara , Rose, Peter S. , Moran, Steven L. , Houdek, Matthew T. , Houdek, Matthew T , Rode, Matthew , Broida, Samuel E.

Mayo Clinic

The Bone & Joint Journal | April 1, 2026 | Volume: 108-B | Issue: 4 | Pages: 561-566

10.1302/0301-620x.108b4.bjj-2025-0889.r1 | PMID 41916538 Get It

Aims A type III internal hemipelvectomy includes resection of the pubic rami. Although bony reconstruction is not necessary, the integrity of the abdominal wall is deficient following resection. The aim of this study was to report the outcome of soft-tissue reconstruction following these resections. Methods We retrospectively reviewed all isolated type III internal hemipelvectomies which were undertaken at the Mayo Clinic (Rochester, USA) between January 2002 and December 2022. The group included 25 patients, of whom 14 (56%) were male. Their median age was 45 years (IQR 61 to 31) at the time of surgery. Most patients (n = 18; 72%) underwent resection for a sarcoma. Soft-tissue flaps were used in 21 patients (84%) and nine also had a mesh reconstruction. Results The five-year disease-specific survival was 65% following surgery, with significantly worse survival in patients with locally advanced tumour (35% (95% CI 12 to 100) vs 76% (95% CI 59 to 99); p = 0.036). Complications were common, with 21 patients (84%) having at least one complication, and 12 (48%) having several complications. Most commonly, this included seroma or haematoma (44%), wound dehiscence (40%), and infection (40%). The use of a soft-tissue flap did not significantly reduce the risk of infection (hazard ratio (HR) 0.68 (95% CI 0.14 to 3.28); p = 0.638) or seroma or haematoma (HR 0.31 (95% CI 0.30 to 4.14); p = 0.088), but patients who did not have a soft-tissue flap were significantly more likely to develop a hernia (odds ratio 9.0 (95% CI 1.14 to 71.03); p = 0.027). A total of three of 21 patients (14%) whose reconstruction involved a flap had donor site complications. Conclusion Soft-tissue reconstruction following a type III internal hemipelvectomy reduces the risk of postoperative hernia formation, with a low rate of donor site complications. This additional procedure should be considered for all patients undergoing this type of resection. Cite this article: Bone Joint J 2026;108-B(4):561–566.
Congenital Cystic Adenomatoid Malformation in the Newborn: Two Case Studies and Review of the Literature
Sittig, Steve E, Asay, Garth F., Sittig, Steven E.

Mayo Clinic

Respiratory Care | March 30, 2026 | Volume: 45 | Issue: 10 | Pages: 1188-1195

10.1177/002013240004501005 Get It

Congenital cystic adenomatoid malformation (CCAM) is a congenital malformation of the lung that can present on imaging studies as abnormal air, air/fluid-filled cysts, or fluid-filled/solid-appearing cysts. The use of ultrasound in prenatal management has increased the number of cases diagnosed in utero. Early diagnosis is vital in the medical management of CCAM. Outcome varies from hydrops and fetal demise to complete resolution before birth. Many CCAMs diagnosed in utero may decrease in size even if substantial mediastinal shift and lung compression are noted at the time of diagnosis. Once the disorder has been diagnosed, use of serial ultrasound is helpful in providing medical management of the fetus. Two cases of CCAM in the newborn are presented that reflect characteristic clinical features but with distinctly different outcomes, one patient successfully re-sponding to resection and ventilatory support, the other succumbing in the first day of life. The embryology, histology, prenatal and postnatal clinical presentation, and treatment of this malfor-mation are discussed on the basis of a review of the literature. Recent developments in fetal diagnosis and treatment, including fetal surgery, are also presented. We conclude that CCAM should be considered in the differential diagnosis in the presence of respiratory distress and me-diastinal shift. It is especially important for respiratory therapists, nurses, and other members of neonatal transport teams to consider CCAM in the differential diagnosis for any patient who presents with respiratory distress and a chest radiograph showing mediastinal shift. The treatment of choice for this lesion is surgical resection by either segmentectomy or lobectomy. Even in cases of relatively asymptomatic patients with CCAM, surgical resection should be considered because of the reported association of carcinoma and unresected CCAM.
Association of GLP-1 receptor agonists versus bariatric surgery with outcomes in obese patients with hypertrophic cardiomyopathy: a multicenter propensity-matched analysis
Mahmoud, Ahmed K, Awad, Kamal, Sheashaa, Hesham, Kandil, Omneya , Farina, Juan M, Ibrahim, Ramzi, Abdelnabi, Mahmoud, Allam, Mohamed , Mital, Rohit , Shipman, Justin , Lester, Steven J, Ommen, Steve R, Geske, Jeffrey B, Patten, Richard D. , Ayoub, Chadi, Arsanjani, Reza, Mahmoud, Ahmed , Mahmoud, Ahmed K , Awad, Kamal , Alsidawi, Said , Ayoub, Chadi , Allam, Mohamed N , Awad, Kamal , Farina, Juan M. , Ibrahim, Ramzi , Abdelnabi, Mahmoud , Alsidawi, Said , Lester, Steven J., Ommen, Steve R. , Geske, Jeffrey B. , Arsanjani, Reza

Mayo Clinic

European Heart Journal - Quality of Care and Clinical Outcomes | March 26, 2026 | Volume: 12 | Issue: 5 | Pages: 731-739

10.1093/ehjqcco/qcag051 | PMID 41910632 Get It

Abstract Aims Obesity is linked with worse outcomes in hypertrophic cardiomyopathy (HCM). While both bariatric surgery (BS) and GLP-1 receptor agonists (GLP-1RA) promote weight loss and may improve cardiometabolic risk, their comparative outcomes in HCM remain unclear. Methods and results Adults with HCM and body mass index (BMI) ≥ 30 kg/m were divided into two cohorts: (i) GLP-1 RA users who never had BS, and (ii) BS patients who never received GLP-1 RA. Propensity score matching (1:1) was performed to balance demographics, comorbidities, and medications. Outcomes over 24 months include all-cause mortality, acute heart failure (HF) hospitalization, arrhythmias, change in BMI, and cardiovascular symptoms. Hazard ratios with 95% confidence intervals were estimated using Cox models. Of 5002 patients, 955 were included in each matched cohort after matching (mean age 54 ± 13 years, 70% female, BMI 40.0 kg/m). GLP-1 RA was associated with a significantly lower observed rate of all-cause mortality compared with BS (2.0% vs. 4.4%; HR 0.46; 95% CI 0.27–0.80; P = 0.004) and HF hospitalization (8.7% vs. 14.0%; HR 0.60; 95% CI 0.46–0.79; P < 0.001). Similarly, GLP-1 RA use was associated with a lower incidence of composite cardiovascular outcomes (10.7% vs. 17.2%; HR 0.60; 95% CI 0.47–0.77; P < 0.001). Rates of arrhythmia and cardiovascular symptoms were comparable between the two groups. BMI reduction was greater after bariatric surgery (−4.0 vs. −2.6 kg/m; P < 0.001). Conclusion In obese patients with HCM, GLP-1 RA therapy was associated with lower all-cause mortality and fewer HF events compared with BS. Future studies are warranted to confirm our findings.
Evolution and Transformation of Hypertrophic Cardiomyopathy From a High Risk to a Treatable Low Mortality Disease With Contemporary Clinical Research Strategies
Maron, Barry J. , Ommen, Steven R., Ra, Nishimura, McKenna, William J. , Rakowski, H., Olivotto, I, Braunwald, Eugene, Maron, Martin S., Nishimura, Rick A. , McKenna, William J. , Olivotto, Iacopo , Ommen, Steve R , Nishimura, Rick A , Rakowski, Harry , Sherrid, Mark , Olivotto, Iacopo , Maron, Martin S , Maron, Barry J. , Ommen, Steve R. , Sherrid, Mark V. , Braunwald, Eugene , Maron, Martin S.

Mayo Clinic

Journal of the American Heart Association | March 25, 2026 | Volume: 15 | Issue: 12 | Pages: No page available

10.1161/jaha.125.047462 | PMID 41878858 Get It

Once considered rare and essentially untreatable with a grim prognosis and reduced life expectancy, hypertrophic cardiomyopathy (HCM) has evolved substantially over 6 decades. Ultimately, HCM has become a contemporary global disease with pharmacologic and interventional options offering effective personalized treatment for all adverse disease pathways. Striking reduction in HCM‐related mortality to ≤0.5%/year in optimally treated cohorts is now comparable to that expected in the US general population, lower than most other disease risks to living, and 10‐fold less than the earliest estimates. The few deaths directly related to HCM are now largely attributable to advanced (end‐stage) heart failure in patients with nonobstructive HCM. Determinants of this transformation to a lower risk disease are evident in hallmark clinical inflection points and breakthroughs, including dedicated HCM programs assembling large clinical databases in which focused (and unfunded) physician‐investigators have derived data directly from patients in clinical practice. Evidence‐based observational studies report emergence of contemporary treatment strategies enhancing survival: implantable defibrillators prevent arrhythmic sudden death globally with 95% sensitive patient selection using an American Heart Association/American College Cardiology risk stratification algorithm; low‐risk, high‐benefit surgical myectomy reverses outflow obstruction and heart failure in >90% with a long‐term survival benefit; and aggressive anticoagulation has reduced embolic strokes. Recent novel pharmacologic alternatives (cardiac myosin inhibitors) are proving effective in relieving obstruction/symptom burden and changing disease management. These principles and time‐tested patient‐centered research strategies uniquely tailored to the heterogeneous HCM clinical spectrum are pivotal in providing practice insights, offering a vulnerable population more optimistic prognosis including opportunity to achieve normal longevity not available to prior generations of patients.
Glucagon-like Peptide-1 Receptor Agonists in Liver Transplant Recipients: A Retrospective Cohort Study
Sheashaa, Hesham, Ibrahim, Ramzi, Elshaer, Amani , Mouhaffel, Rama, Habib, E., Abdelnabi, Mahmoud, Farina, Juan M., Lester, Steven J., Simper, David, Steidley, Eric, Aqel, B., Barnhill, Michele , Kim, W. Ray, Ayoub, Chadi, Arsanjani, Reza, Ibrahim, Ramzi , Ibrahim, Ramzi , Steidley, Eric D, Pham, Hoang Nhat , Abdelnabi, Mahmoud , Farina, Juan M., Alsidawi, Said , Aqel, Bashar A. , Arsanjani, Reza

Mayo Clinic

Transplantation Direct | March 23, 2026 | Volume: 12 | Issue: 4 | Pages: e1932

10.1097/txd.0000000000001932 | PMID 41884702 Get It

Background. Liver transplant recipients face high risks of cardiometabolic events after transplant, driven by posttransplant weight gain, diabetes, hypertension, as well as immunosuppression-related side effects. Glucagon-like peptide-1 receptor agonists (GLP1RAs) improve metabolic and cardiorenal outcomes in nontransplant populations, but their role in liver transplant recipients remains understudied. Methods. This retrospective cohort study used TriNetX data (January 2010–December 2023) to compare outcomes in liver transplant recipients prescribed GLP1RAs (semaglutide, dulaglutide, liraglutide) within 1-mo posttransplant (n = 546) versus nonusers (n = 37 153). Propensity score matching (1:1) balanced demographics, comorbidities, and medications (n = 541 per group). Outcomes included mortality, hospitalizations, cardiovascular/renal/respiratory events, and graft outcomes. Results. Over a mean follow-up 838.5 d (SD 291.9) in the GLP1RA cohort and 884.3 d (SD 313.7) in the non-GLP1RA group, GLP1RA use was associated with a 43% lower all-cause mortality (7.0% versus 12.9%; hazard ratio [HR], 0.566; 95% confidence interval [CI], 0.381-0.841) and 39% fewer hospitalizations (60.4% versus 74.5%; HR, 0.613; 95% CI, 0.530-0.710). Acute heart failure (HR, 0.386; 95% CI, 0.285-0.524), renal failure/dialysis (HR, 0.489; 95% CI, 0.413-0.579), and respiratory failure (HR, 0.484; 95% CI, 354-0.662) risks were significantly reduced. No differences were observed in graft failure/rejection, myocardial infarction, stroke, atrial fibrillation/flutter, ventricular tachycardia, or ischemic optic neuropathy. Conclusions. Early GLP1RA initiation in liver transplant recipients was associated with reduced mortality, hospitalizations, respiratory, and cardiorenal complications without compromising graft safety. These findings support GLP1RAs as a promising adjunct therapy, warranting prospective trials to confirm benefits in this high-risk population.
Handbook of Bioterrorism and Disaster Medicine.
Sittig, Steven E.

Mayo Clinic

Respiratory Care | March 12, 2026 | Volume: 52 | Issue: 11 | Pages: 1546-1547

10.4187/respcare.07521546 Get It

The CARE framework for AI dataset documentation in clinical laboratories: a comprehensive checklist and data lineage methodology
Garcia, Christopher A., Reed, Katelyn A. , Lantz, Eric, Day, Patrick L. , Stadler, Brian C, Zarella, Mark D. , Hart, Steven N. , Han, Wenchao, Wahsh, Ezzaddin Al, Novak, Debra, McClintock, David S. , Day, Patrick , Tavolara, Thomas E, Al Wahsh, Ezzaddin, Novak, Debra A, McClintock, David S , Hart, Steven N , Lantz, Eric, Han, Wenchao, Tavolara, Thomas Erol , Wahsh, EzzAddin Al, Novak, Debra A

Mayo Clinic

American Journal of Clinical Pathology | March 7, 2026 | Volume: 165 | Issue: 5 | Pages: No page available

10.1093/ajcp/aqag029 | PMID 42114029 Get It

Abstract Objectives Traditional laboratory regulatory frameworks provide robust guidance for conventional clinical testing but lack requirements for data documentation for artificial intelligence and machine learning (AI/ML) solutions. This gap creates significant risks since AI solutions directly inherit patterns, biases, and limitations from their training data. Here, we describe the development and implementation of a comprehensive data documentation checklist with accompanying data lineage for use within an AI lifecycle framework for clinical laboratories. Methods Building on the previously established Clinical AI Readiness Evaluator (CARE) framework, we developed a comprehensive data checklist and data lineage methodology through a multiphase process, including (1) comprehensive review of existing AI/ML data documentation frameworks, (2) focused meetings with 3 institutional AI operations teams, and (3) 3 rounds of iterative refinement by our multidisciplinary team. The checklist’s effectiveness was then assessed using 3 diverse AI/ML projects moving through the CARE framework. Results The CARE Data Checklist and Data Lineage provide a structured approach to documenting critical aspects of datasets used in AI/ML projects, including data composition, demographics, collection methods, labeling processes, usage constraints, maintenance requirements, and a data readiness assessment. The checklist addresses unique data-centric challenges of AI/ML applications, facilitating transparency, reproducibility, and regulatory compliance. Conclusions The CARE Data Checklist and Data Lineage serve as both a technical guide and a communication tool bridging gaps between technical and clinical stakeholders. By working on these documents early in the AI lifecycle, laboratories can anticipate and address data-related challenges, ultimately saving time, optimizing resources, and improving the reliability of AI-augmented laboratory solutions.